Epoprostenol
Epoprostenol Brand names, Epoprostenol Analogs
Epoprostenol Brand Names Mixture
- No information avaliable
Epoprostenol Chemical_Formula
C20H32O5
Epoprostenol RX_link
http://www.rxlist.com/cgi/generic/flolan.htm
Epoprostenol fda sheet
Epoprostenol msds (material safety sheet)
Epoprostenol Synthesis Reference
No information avaliable
Epoprostenol Molecular Weight
352.465 g/mol
Epoprostenol Melting Point
No information avaliable
Epoprostenol H2O Solubility
No information avaliable
Epoprostenol State
Solid
Epoprostenol LogP
2.543
Epoprostenol Dosage Forms
Powder for solution
Epoprostenol Indication
For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Epoprostenol Pharmacology
Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.
Epoprostenol Absorption
No information avaliable
Epoprostenol side effects and Toxicity
Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.
Epoprostenol Patient Information
Epoprostenol Organisms Affected
Humans and other mammals
